NCT07146321尚未招募不适用
A Randomized, Double-blinded, Placebo-controlled Study to Investigate the Effect of a Multivitamin, Multi-nutrient Supplement on Mental and Emotional Wellbeing in Females Aged 43 - 55 Years
Biologica Inc2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2025年9月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 80
- 试验地点
- 2
- 主要终点
- Psychosocial symptoms associated with menopause
研究概览
简要总结
This is a randomized, double-blinded, parallel, placebo-controlled study to investigate the effect of a multivitamin, multi-nutrient supplement on mental and emotional wellbeing in healthy females aged 43 to 55 years, experiencing peri-menopausal and menopausal symptoms
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 43 Years 至 55 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Be able to give written informed consent.
- •Be between 43 and 55, inclusive.
- •Experiencing a score of >4 on 3 of the symptoms below, within the past 12-months, measured by the MenQoL at Visit
- •feeling anxious or nervous
- •difficulty sleeping
- •feeling tired or worn out
- •being impatient with other people
- •Ability to wear and interact with a wearable device (ring) for biomarker tracking.
- •Has a minimum 7 days of Oura ring data
- •Willing to consume the Study Product daily for the duration of the study.
排除标准
- •Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.
- •Participants currently of biological childbearing potential, but not using a continuous effective method of contraception, as outlined below:
- •Complete abstinence from intercourse two weeks prior to administration of the Study Product, throughout the clinical study, until the completion of follow-up procedures or for two weeks following discontinuation of the Study Product in cases where Participant discontinues the study prematurely. (Participants utilizing this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding two weeks when they present to the clinic for the final visit).
- •Has a male sexual partner who is surgically sterilized prior to the Screening Visit and is the only male sexual partner for that Participant.
- •Sexual partner(s) is/are exclusively female.
- •Use of acceptable method of contraception, such as a spermicide, mechanical barrier (e.g., male condom, female diaphragm), or tubal ligation. The Participant must be using this method for at least one week prior to and one week following the end of the study.
- •Use of any non-hormonal intrauterine device (IUD). The Participant must have the device inserted at least two weeks prior to the first screening visit, throughout the study, and two weeks following the end of the study.
- •Drinks more than nationally recommended units of alcohol per day/week. (Defined as <7 standard drinks per week, spread out over the week, with 2 to 3 alcohol-free days per week. Drinks no more than 3 standard drinks on any 1 occasion).
- •Has a history of drug and/or alcohol abuse.
- •Hypersensitivity that would preclude intake of the Study Products
- •Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include:
- •Uterine fibroids (current or previous 12 months)
- •Polycystic ovarian syndrome
- •Psychiatric disorders (e.g. bipolar, schizophrenia)
- •Current or recent (in the past 12-weeks) use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include:
- •Hypnotic-sedative drugs or sleep aids
- •Psychotropics (e.g., treatment of anxiety, depression, ADHD etc.)
- •Steroids (inhaled, intravenous, or oral).
- •Current or recent (in the past 1-week) use of prohibited nutritional or non-nutritional supplements that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited supplements include:
- •Supplements for the support of menopause symptoms (e.g., red clover, wild yam supplements/creams, ginseng, St John's Wort, DHEA supplements, Phytoestrogen supplements, hormone support supplements)
- •Supplements that contain study product ingredients
- •Supplements that support mood and sleep
- •Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.
- •Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.
结局指标
主要结局
Psychosocial symptoms associated with menopause
时间窗: 12 weeks
Change in mental and emotional symptoms in menopause in the multivitamin, multi-nutrient supplement group compared to Placebo. Assessed by the Menopause-specific Quality of Life Questionnaire (MenQoL) - psychosocial domain score. Baseline to end of intervention (week 12).
次要结局
- Sexual symptoms of menopause(12 weeks)
- Physical symptoms of menopause(12 weeks)
- Vasomotor symptoms of menopause(12 weeks)
- Impact to stress(12 weeks)
- Impact to anxiety(12 weeks)
- Impact to working memory(12 weeks)
- Impact to sleep efficiency(12 weeks)
- Impact to sleep latency(12 weeks)
- Impact to total sleep time(12 weeks)
- Impact to sleep disturbances(12 weeks)
- Sleep related impairment(12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Investigating the Efficacy of Brain Octane® Oil on Cognition, Coordination, Reaction Time and Measurements of Physical Performance in Recreationally Active AdultsHealthyNCT04095728Bulletproof 360, Inc.30
已完成
2 期
A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With DiabetesEfficacySafetyPharmacokineticsDiabetes Mellitus, Type 2NCT05353686Pila Pharma54
已完成
2/3 期
A clinical study of KaraHeart for the management of cholesterol level in human participants.CTRI/2020/07/026907GreenChem100
已完成
1 期
A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With LisinoprilDiabetes Mellitus Type 2NCT01398267Hoffmann-La Roche55
已完成
3 期
A clinical trial to study whether zinc decreases the frequency of disease relapses in patients with frequently relapsing nephrotic syndromeCTRI/2008/091/000057114